PubMed Health⌕ Search

Biomedical subjects

J D Phillips

Publications and source records attributed to J D Phillips.

88 records · Page 5Linked to original sources
PubMed1977

A new coagulation defect associated with a case of melanomatosis.

A marked abnormality of the intrinsic coagulation system was observed in a patient with melanomatosis and frank melanuria. With successful treatment of the tumour there was a parallel improvement in the clotting abnormality. This defect was shown to be a deficiency of factor XI together with a previously unrecognised factor. This is distinct from either Fletcher or Fitzgerald factors and appears to act between factors XI and X in the coagulation sequence.

Adult↗
PubMed1975

Prosthetic implications of Eagle's syndrome.

Eagle's syndrome can produce symptoms that may be easily confused with those resulting from wearing a prosthetic restoration. The symptoms resulting from elongated styloid processes and methods of diagnosis and treatment of these processes were described. A patient with Eagle's syndrome has been presented. The symptoms were initially suspected to be due to an ill-fitting mandibular removable partial denture. Further clinical and radiographic examination led to the diagnosis of Eagle's syndrome, and surgical correction was done. The prosthodontist should consider surgery as a possible treatment when the symptoms of the syndrome cannot be attributed to a prosthetic restoration. Various radiographic projections and panoramic radiography are valuable in confirming the presence of a calcified stylohyoid ligament or an elongated styloid process.

Carotid Artery Diseases↗
PubMedDate not supplied

The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.

Lithium has been known for its ability to induce the production of hematopoietic cells following administration in vivo to minimize the toxic effects on hematopoiesis as a consequence of drug treatment. The drug hydroxyurea (HU), a ribonucleotide reductase inhibitor, has been used in the treatment of a variety of neoplastic and non-neoplastic diseases, such as cancer and sickle cell anaemia. Hydroxyurea has more recently been implicated for use in the treatment of acquired immunodeficiency syndrome (AIDS). However, its major limitations have been due to its toxicity. Hydroxyurea selectively inhibits DNA synthesis and due to its brief duration, the drug is only toxic to those cells which are selectively synthesizing DNA during the period of exposure. The most important of these toxicities, and which serves as a dose limiting factor in treatment, is the induction of bone marrow suppression. In this study we investigated the possible beneficial effects of administering lithium (LiCl) to murine leukemia virus (MuLV) infected and non-infected long term bone marrow cultures (LTBMC). These cultures were then treated with either 0.2 mM hydroxyurea, 1.0 mM LiCl, or a combination of both. Samples were collected from LTBMC supernatants at 1, 2, 3, 4, 5 and 6 weeks post-treatment. Culture supernatants were then monitored to observe their repopulation of hematopoietic progenitors. The results demonstrated the effects of lithium in restoring hydroxyurea suppressed numbers of myeloid (CFU-GM) progenitors to within a normal range and also in re-establishing erythroid (BFU-E) progenitors.

Animals↗